Prostate cancer: Positive targeted cores increase upgradation risk in active surveillance

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.

Key clinical point: In patients with low-intermediate prostate cancer undergoing active surveillance, Gleason grade group (GG) 2 and positive targeted core are associated with significant risk for upgradation.

Major finding: At a median follow-up of 4.8 years, GG upgraded in 92 patients. GG2 (hazard ratio [HR], 2.93; 95% CI, 1.05-8.19) and 1 and more than 1 positive targeted cores (HR, 2.75; 95% CI, 1.25-6.03 and HR, 3.38; 95% CI, 1.65-6.91, respectively) at confirmatory magnetic resonance imaging (MRI)-guided biopsy were significant risk factor of upgradation.

Study details: A prospective study of 519 men with GG 1 and GG 2 prostate cancer undergoing active surveillance, who received confirmatory targeted and systemic MRI-guided biopsy followed by surveillance MRI-guided biopsy every 12 to 24 months.

Disclosures: This work was supported by National Cancer Institute, Center for Interventional Oncology, University of California, and others. Dr. L.S. Marks and Dr. A. Priester reported association with Avenda Health. No other competing interests were reported.

Source: Kinnaird A et al. J Urol. 2021 Dec 2. doi: 10.1097/JU.0000000000002343.